Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Мукоактивная терапия. Перспективы применения в оториноларингологии
Мукоактивная терапия. Перспективы применения в оториноларингологии
Карпищенко С.А., Алексеенко С.И., Колесникова О.М. Мукоактивная терапия. Перспективы применения в оториноларингологии. Consilium Medicum. 2017; 19 (3): 44–49.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье представлен обзор мукоактивных препаратов, наиболее часто используемых для лечения воспалительных заболеваний верхних дыхательных путей. Описаны влияние ацетилцистеина на бактериальные биопленки и его клиническая эффективность в сочетании с антибактериальным препаратом в эрадикации бактериальных возбудителей. Представлен клинический случай успешного лечения ребенка 8 лет с обострением гнойного полисинусита комбинацией препаратов с ацетилцистеином.
Ключевые слова: мукоактивная терапия, ацетилцистеин, острый синусит.
Ключевые слова: мукоактивная терапия, ацетилцистеин, острый синусит.
________________________________________________
This article deals with the overview concerning mucoactive drugs, most commonly used for the treatment of inflammatory diseases of the upper respiratory tract. The overview describes the effect of acetylcysteine on bacterial biofilms and the clinical efficacy of combination of acetylcysteine and antibacterial drug in eradication of bacterial pathogens. The authors show the clinical case of successful treatment of 8 years old child with the relapse of purulent polysinusitis, using combination of drugs and acetylcysteine.
Key words: mucoactive therapy, acetylcysteine, acute sinusitis.
Key words: mucoactive therapy, acetylcysteine, acute sinusitis.
Полный текст
Список литературы
1. Mall MA. Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J Aerosol Med Pulm Drug Deliv 2008; 21 (1): 13–24. DOI: 10.1089/jamp.2007.0659.
2. Teff Z, Priel Z, Ghebery LA. Forces Applied by Cilia Measured on Explants from Mucociliary Tissue. Biophys J 2007; 92: 1813–23. DOI: 10.1529/biophysj.106.094698.
3. Rubin BK. Secretion properties, clearance, and therapy in airway disease. Transl Respir Med 2014; 2: 6. DOI: 10.1186/2213-0802-2-6.
4. Rubin BK. The pharmacologic approach to airway clearance: mucoactive agents. Respir Care 2002; 47: 818–22.
5. Balsamo R, Lanata L, Egan CG. Mucoactive drugs Eur. Respir Rev 2010; 19: 116, 127–33. DOI: 10.1183/09059180.00003510.
6. Yuta A, Baraniuk JN. Therapeutic approaches to airway hypersecretion. Curr Allergy Asthma Rep 2005; 5: 243–51. PMID: 15842963.
7. Low TH, Woods CM, Ullah S, Carney AS. A double-blind randomized controlled trial of normal saline, lactated Ringer's, and hypertonic saline nasal irrigation solution after endoscopic sinus surgery. Am J Rhinol Allergy 2014; 28 (3): 225–31. DOI: 10.2500/ajra.2014.28.4031.
8. Симонова О.И. Муколитическая терапия в педиатрии: мифы и реальность. Педиатрич. фармакология. 2009; 6 (2): 72–5. / Simonova O.I. Mukoliticheskaia terapiia v pediatrii: mify i real'nost'. Pediatrich. farmakologiia. 2009; 6 (2): 72–5. [in Russian]
9. Блоцкий А.А., Цепляев М.Ю. Эффективность комплексной терапии острых и хронических синуситов с применением препаратов из группы природных секретолитиков. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2015; 21 (3): 47–53. / Blotskii A.A., Tsepliaev M.Iu. Effektivnost' kompleksnoi terapii ostrykh i khronicheskikh sinusitov s primeneniem preparatov iz gruppy prirodnykh sekretolitikov. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2015; 21 (3): 47–53. [in Russian]
10. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol 2008; 4: 1119–29. DOI: 10.1517/17425255.4.8.1119.
11. Agnew JE, Bateman JRM, Pavia D, Clarke SW. Peripheral airways mucus clearance in stable asthma is improved by oral corticosteroid therapy. Bull Eur Physiopath Respir 1984; 20: 295–301.
12. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004; 125: 52–60. PMID: 14872001.
13. Dąbrowski P, Leszczyńska M, Mielcarek-Kuchta D. The role of carbocystein in the treatment of sinusitis. Otolaryngol Pol 2012; 66 (4): 15–9. DOI: 10.1016/S0030-6657(12)70779-5.
14. Carpagnano GE, Resta O, Foschino-Barbaro MP et al. Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate. Eur J Pharmacol 2004; 505: 169–75.
15. McPhail GL, Acton JD, Fenchel MC et al. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr 2008; 153: 752–7. DOI: 10.1016/j.jpeds.2008.07.011.
16. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 629–36.
17. Tirouvanziam R, Conrad CK, Bottiglieri T et al. High-dose oral Nacetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006; 103: 4628–33. DOI: 10.1073/pnas.0511304103.
18. Linden M, Wieslander E, Eklund A et al. Effects of oral Nacetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur Respir J 1988; 1: 645–50.
19. Eklund A, Eriksson O, Hakansson L et al. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J 1988; 1: 832–8.
20. Niederman MS, Rafferty TD, Sasaki CT et al. Comparison of bacterial adherence to ciliated and squamous epithelial cells obtained from the human respiratory tract. Am Rev Respir Dis 1983; 127: 85–90. DOI: 10.1164/arrd.1983.127.1.85.
21. Guibas GV, Spandou E, Meditskou S et al. N-acetylcysteine exerts therapeutic action in a rat model of allergic rhinitis. Int Forum Allergy Rhinol 2013; 3 (7): 543–9. DOI: 10.1002/alr.21145.
22. Boman G, Bäcker U, Larsson S et al. Oral acetyl cystine reduces exacerbation rate in chronic bronchitis, report of a trial organized by the Swedish Society for Pulmonary Disease. Eur J Respir Dis 1983; 64: 405–15.
23. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 29 (7): CD001287. DOI: 10.1002/14651858.CD001287.pub5.
24. Moretti M, Marchioni CF. An overview of erdosteine antioxidant activity in experimental research. Pharmacol Res 2007; 55: 249–54. DOI: 10.1016/j.phrs.2006.12.006.
25. Rhee CK, Kang CM, You MB et al. Effect of fudosteine on mucin production. Eur Respir J 2008; 32: 1195–202. DOI: 10.1183/09031936.00018508.
26. Оториноларингология: национальное руководство. Под ред. В.Т.Пальчуна. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2016. / Otorinolaringologiia: natsional'noe rukovodstvo. Pod red. V.T.Pal'chuna. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2016. [in Russian]
27. McNeer RR, Huang D, Fregien NL, Carraway KL. Sialomucin complex in the rat respiratory tract: a model for its role in epithelial protection. Biochem J 1998; 330 (2): 737–44.
28. Perez-Giraldo C, Rodriguez-Benito A, Moran FJ et al. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. JAC 1997; 39: 643–6.
29. Drago L, De Vecchi E, Mattina R, Romanò CL. Activity of N-acetyl-L-cysteine against biofilm of Staphylococcus aureus and Pseudomonas aeruginosa on orthopedic prosthetic materials. Int J Artif Organs 2013; 36 (1): 39–46. DOI: 10.5301/ijao.5000135.
30. Leite B, Gomes F, Teixeira P et al. Combined effect of linezolid and N-acetylcysteine against Staphylococcus epidermidis biofilms. Enferm Infecc Microbiol Clin 2013; 31 (10): 655–9. DOI: 10.1016/j.eimc.2012.11.011.
31. Citation LG, Di MT, Sergio F et al. Effect of high N-acetylcysteine concentrations on antibiotic activity against a large collection of respiratory pathogens. Antimicrob Agents Chemother 2016; 60: 7513–7. DOI: 10.1128/AAC.01334-16.
32. Schwandt LQ, Van Weissenbruch R, Stokroos I et al. Prevention of biofilm formation by dairy products and N-acetylcysteine on voice prostheses in an artificial throat. Acta Otolaryngol 2004; 124 (6): 726–31.
33. Dinicola S, De Grazia S, Carlomagno G, Pintucci JP. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol 2014; 18 (19): 2942–8.
34. Macchi A, Ardito F, Marchese A et al. Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms. J Chemother 2006; 18 (5): 507–13. DOI: 10.1179/joc.2006.18.5.507.
35. Садовский В.И., Сухарев А.А., Черныш А.В. Современное лечение гнойной инфекции в оториноларингологии. Оториноларингология Восточная Европа. 2016; 1 (22): 140–3. / Sadovskii V.I., Sukharev A.A., Chernysh A.V. Sovremennoe lechenie gnoinoi infektsii v otorinolaringologii. Otorinolaringologiia Vostochnaia Evropa. 2016; 1 (22): 140–3. [in Russian]
2. Teff Z, Priel Z, Ghebery LA. Forces Applied by Cilia Measured on Explants from Mucociliary Tissue. Biophys J 2007; 92: 1813–23. DOI: 10.1529/biophysj.106.094698.
3. Rubin BK. Secretion properties, clearance, and therapy in airway disease. Transl Respir Med 2014; 2: 6. DOI: 10.1186/2213-0802-2-6.
4. Rubin BK. The pharmacologic approach to airway clearance: mucoactive agents. Respir Care 2002; 47: 818–22.
5. Balsamo R, Lanata L, Egan CG. Mucoactive drugs Eur. Respir Rev 2010; 19: 116, 127–33. DOI: 10.1183/09059180.00003510.
6. Yuta A, Baraniuk JN. Therapeutic approaches to airway hypersecretion. Curr Allergy Asthma Rep 2005; 5: 243–51. PMID: 15842963.
7. Low TH, Woods CM, Ullah S, Carney AS. A double-blind randomized controlled trial of normal saline, lactated Ringer's, and hypertonic saline nasal irrigation solution after endoscopic sinus surgery. Am J Rhinol Allergy 2014; 28 (3): 225–31. DOI: 10.2500/ajra.2014.28.4031.
8. Simonova O.I. Mukoliticheskaia terapiia v pediatrii: mify i real'nost'. Pediatrich. farmakologiia. 2009; 6 (2): 72–5. [in Russian]
9. Blotskii A.A., Tsepliaev M.Iu. Effektivnost' kompleksnoi terapii ostrykh i khronicheskikh sinusitov s primeneniem preparatov iz gruppy prirodnykh sekretolitikov. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2015; 21 (3): 47–53. [in Russian]
10. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol 2008; 4: 1119–29. DOI: 10.1517/17425255.4.8.1119.
11. Agnew JE, Bateman JRM, Pavia D, Clarke SW. Peripheral airways mucus clearance in stable asthma is improved by oral corticosteroid therapy. Bull Eur Physiopath Respir 1984; 20: 295–301.
12. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004; 125: 52–60. PMID: 14872001.
13. Dąbrowski P, Leszczyńska M, Mielcarek-Kuchta D. The role of carbocystein in the treatment of sinusitis. Otolaryngol Pol 2012; 66 (4): 15–9. DOI: 10.1016/S0030-6657(12)70779-5.
14. Carpagnano GE, Resta O, Foschino-Barbaro MP et al. Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate. Eur J Pharmacol 2004; 505: 169–75.
15. McPhail GL, Acton JD, Fenchel MC et al. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr 2008; 153: 752–7. DOI: 10.1016/j.jpeds.2008.07.011.
16. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 629–36.
17. Tirouvanziam R, Conrad CK, Bottiglieri T et al. High-dose oral Nacetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006; 103: 4628–33. DOI: 10.1073/pnas.0511304103.
18. Linden M, Wieslander E, Eklund A et al. Effects of oral Nacetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur Respir J 1988; 1: 645–50.
19. Eklund A, Eriksson O, Hakansson L et al. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J 1988; 1: 832–8.
20. Niederman MS, Rafferty TD, Sasaki CT et al. Comparison of bacterial adherence to ciliated and squamous epithelial cells obtained from the human respiratory tract. Am Rev Respir Dis 1983; 127: 85–90. DOI: 10.1164/arrd.1983.127.1.85.
21. Guibas GV, Spandou E, Meditskou S et al. N-acetylcysteine exerts therapeutic action in a rat model of allergic rhinitis. Int Forum Allergy Rhinol 2013; 3 (7): 543–9. DOI: 10.1002/alr.21145.
22. Boman G, Bäcker U, Larsson S et al. Oral acetyl cystine reduces exacerbation rate in chronic bronchitis, report of a trial organized by the Swedish Society for Pulmonary Disease. Eur J Respir Dis 1983; 64: 405–15.
23. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 29 (7): CD001287. DOI: 10.1002/14651858.CD001287.pub5.
24. Moretti M, Marchioni CF. An overview of erdosteine antioxidant activity in experimental research. Pharmacol Res 2007; 55: 249–54. DOI: 10.1016/j.phrs.2006.12.006.
25. Rhee CK, Kang CM, You MB et al. Effect of fudosteine on mucin production. Eur Respir J 2008; 32: 1195–202. DOI: 10.1183/09031936.00018508.
26. Otorinolaringologiia: natsional'noe rukovodstvo. Pod red. V.T.Pal'chuna. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2016. [in Russian]
27. McNeer RR, Huang D, Fregien NL, Carraway KL. Sialomucin complex in the rat respiratory tract: a model for its role in epithelial protection. Biochem J 1998; 330 (2): 737–44.
28. Perez-Giraldo C, Rodriguez-Benito A, Moran FJ et al. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. JAC 1997; 39: 643–6.
29. Drago L, De Vecchi E, Mattina R, Romanò CL. Activity of N-acetyl-L-cysteine against biofilm of Staphylococcus aureus and Pseudomonas aeruginosa on orthopedic prosthetic materials. Int J Artif Organs 2013; 36 (1): 39–46. DOI: 10.5301/ijao.5000135.
30. Leite B, Gomes F, Teixeira P et al. Combined effect of linezolid and N-acetylcysteine against Staphylococcus epidermidis biofilms. Enferm Infecc Microbiol Clin 2013; 31 (10): 655–9. DOI: 10.1016/j.eimc.2012.11.011.
31. Citation LG, Di MT, Sergio F et al. Effect of high N-acetylcysteine concentrations on antibiotic activity against a large collection of respiratory pathogens. Antimicrob Agents Chemother 2016; 60: 7513–7. DOI: 10.1128/AAC.01334-16.
32. Schwandt LQ, Van Weissenbruch R, Stokroos I et al. Prevention of biofilm formation by dairy products and N-acetylcysteine on voice prostheses in an artificial throat. Acta Otolaryngol 2004; 124 (6): 726–31.
33. Dinicola S, De Grazia S, Carlomagno G, Pintucci JP. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol 2014; 18 (19): 2942–8.
34. Macchi A, Ardito F, Marchese A et al. Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms. J Chemother 2006; 18 (5): 507–13. DOI: 10.1179/joc.2006.18.5.507.
35. Sadovskii V.I., Sukharev A.A., Chernysh A.V. Sovremennoe lechenie gnoinoi infektsii v otorinolaringologii. Otorinolaringologiia Vostochnaia Evropa. 2016; 1 (22): 140–3. [in Russian]
2. Teff Z, Priel Z, Ghebery LA. Forces Applied by Cilia Measured on Explants from Mucociliary Tissue. Biophys J 2007; 92: 1813–23. DOI: 10.1529/biophysj.106.094698.
3. Rubin BK. Secretion properties, clearance, and therapy in airway disease. Transl Respir Med 2014; 2: 6. DOI: 10.1186/2213-0802-2-6.
4. Rubin BK. The pharmacologic approach to airway clearance: mucoactive agents. Respir Care 2002; 47: 818–22.
5. Balsamo R, Lanata L, Egan CG. Mucoactive drugs Eur. Respir Rev 2010; 19: 116, 127–33. DOI: 10.1183/09059180.00003510.
6. Yuta A, Baraniuk JN. Therapeutic approaches to airway hypersecretion. Curr Allergy Asthma Rep 2005; 5: 243–51. PMID: 15842963.
7. Low TH, Woods CM, Ullah S, Carney AS. A double-blind randomized controlled trial of normal saline, lactated Ringer's, and hypertonic saline nasal irrigation solution after endoscopic sinus surgery. Am J Rhinol Allergy 2014; 28 (3): 225–31. DOI: 10.2500/ajra.2014.28.4031.
8. Симонова О.И. Муколитическая терапия в педиатрии: мифы и реальность. Педиатрич. фармакология. 2009; 6 (2): 72–5. / Simonova O.I. Mukoliticheskaia terapiia v pediatrii: mify i real'nost'. Pediatrich. farmakologiia. 2009; 6 (2): 72–5. [in Russian]
9. Блоцкий А.А., Цепляев М.Ю. Эффективность комплексной терапии острых и хронических синуситов с применением препаратов из группы природных секретолитиков. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2015; 21 (3): 47–53. / Blotskii A.A., Tsepliaev M.Iu. Effektivnost' kompleksnoi terapii ostrykh i khronicheskikh sinusitov s primeneniem preparatov iz gruppy prirodnykh sekretolitikov. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2015; 21 (3): 47–53. [in Russian]
10. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol 2008; 4: 1119–29. DOI: 10.1517/17425255.4.8.1119.
11. Agnew JE, Bateman JRM, Pavia D, Clarke SW. Peripheral airways mucus clearance in stable asthma is improved by oral corticosteroid therapy. Bull Eur Physiopath Respir 1984; 20: 295–301.
12. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004; 125: 52–60. PMID: 14872001.
13. Dąbrowski P, Leszczyńska M, Mielcarek-Kuchta D. The role of carbocystein in the treatment of sinusitis. Otolaryngol Pol 2012; 66 (4): 15–9. DOI: 10.1016/S0030-6657(12)70779-5.
14. Carpagnano GE, Resta O, Foschino-Barbaro MP et al. Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate. Eur J Pharmacol 2004; 505: 169–75.
15. McPhail GL, Acton JD, Fenchel MC et al. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr 2008; 153: 752–7. DOI: 10.1016/j.jpeds.2008.07.011.
16. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 629–36.
17. Tirouvanziam R, Conrad CK, Bottiglieri T et al. High-dose oral Nacetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006; 103: 4628–33. DOI: 10.1073/pnas.0511304103.
18. Linden M, Wieslander E, Eklund A et al. Effects of oral Nacetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur Respir J 1988; 1: 645–50.
19. Eklund A, Eriksson O, Hakansson L et al. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J 1988; 1: 832–8.
20. Niederman MS, Rafferty TD, Sasaki CT et al. Comparison of bacterial adherence to ciliated and squamous epithelial cells obtained from the human respiratory tract. Am Rev Respir Dis 1983; 127: 85–90. DOI: 10.1164/arrd.1983.127.1.85.
21. Guibas GV, Spandou E, Meditskou S et al. N-acetylcysteine exerts therapeutic action in a rat model of allergic rhinitis. Int Forum Allergy Rhinol 2013; 3 (7): 543–9. DOI: 10.1002/alr.21145.
22. Boman G, Bäcker U, Larsson S et al. Oral acetyl cystine reduces exacerbation rate in chronic bronchitis, report of a trial organized by the Swedish Society for Pulmonary Disease. Eur J Respir Dis 1983; 64: 405–15.
23. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 29 (7): CD001287. DOI: 10.1002/14651858.CD001287.pub5.
24. Moretti M, Marchioni CF. An overview of erdosteine antioxidant activity in experimental research. Pharmacol Res 2007; 55: 249–54. DOI: 10.1016/j.phrs.2006.12.006.
25. Rhee CK, Kang CM, You MB et al. Effect of fudosteine on mucin production. Eur Respir J 2008; 32: 1195–202. DOI: 10.1183/09031936.00018508.
26. Оториноларингология: национальное руководство. Под ред. В.Т.Пальчуна. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2016. / Otorinolaringologiia: natsional'noe rukovodstvo. Pod red. V.T.Pal'chuna. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2016. [in Russian]
27. McNeer RR, Huang D, Fregien NL, Carraway KL. Sialomucin complex in the rat respiratory tract: a model for its role in epithelial protection. Biochem J 1998; 330 (2): 737–44.
28. Perez-Giraldo C, Rodriguez-Benito A, Moran FJ et al. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. JAC 1997; 39: 643–6.
29. Drago L, De Vecchi E, Mattina R, Romanò CL. Activity of N-acetyl-L-cysteine against biofilm of Staphylococcus aureus and Pseudomonas aeruginosa on orthopedic prosthetic materials. Int J Artif Organs 2013; 36 (1): 39–46. DOI: 10.5301/ijao.5000135.
30. Leite B, Gomes F, Teixeira P et al. Combined effect of linezolid and N-acetylcysteine against Staphylococcus epidermidis biofilms. Enferm Infecc Microbiol Clin 2013; 31 (10): 655–9. DOI: 10.1016/j.eimc.2012.11.011.
31. Citation LG, Di MT, Sergio F et al. Effect of high N-acetylcysteine concentrations on antibiotic activity against a large collection of respiratory pathogens. Antimicrob Agents Chemother 2016; 60: 7513–7. DOI: 10.1128/AAC.01334-16.
32. Schwandt LQ, Van Weissenbruch R, Stokroos I et al. Prevention of biofilm formation by dairy products and N-acetylcysteine on voice prostheses in an artificial throat. Acta Otolaryngol 2004; 124 (6): 726–31.
33. Dinicola S, De Grazia S, Carlomagno G, Pintucci JP. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol 2014; 18 (19): 2942–8.
34. Macchi A, Ardito F, Marchese A et al. Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms. J Chemother 2006; 18 (5): 507–13. DOI: 10.1179/joc.2006.18.5.507.
35. Садовский В.И., Сухарев А.А., Черныш А.В. Современное лечение гнойной инфекции в оториноларингологии. Оториноларингология Восточная Европа. 2016; 1 (22): 140–3. / Sadovskii V.I., Sukharev A.A., Chernysh A.V. Sovremennoe lechenie gnoinoi infektsii v otorinolaringologii. Otorinolaringologiia Vostochnaia Evropa. 2016; 1 (22): 140–3. [in Russian]
________________________________________________
2. Teff Z, Priel Z, Ghebery LA. Forces Applied by Cilia Measured on Explants from Mucociliary Tissue. Biophys J 2007; 92: 1813–23. DOI: 10.1529/biophysj.106.094698.
3. Rubin BK. Secretion properties, clearance, and therapy in airway disease. Transl Respir Med 2014; 2: 6. DOI: 10.1186/2213-0802-2-6.
4. Rubin BK. The pharmacologic approach to airway clearance: mucoactive agents. Respir Care 2002; 47: 818–22.
5. Balsamo R, Lanata L, Egan CG. Mucoactive drugs Eur. Respir Rev 2010; 19: 116, 127–33. DOI: 10.1183/09059180.00003510.
6. Yuta A, Baraniuk JN. Therapeutic approaches to airway hypersecretion. Curr Allergy Asthma Rep 2005; 5: 243–51. PMID: 15842963.
7. Low TH, Woods CM, Ullah S, Carney AS. A double-blind randomized controlled trial of normal saline, lactated Ringer's, and hypertonic saline nasal irrigation solution after endoscopic sinus surgery. Am J Rhinol Allergy 2014; 28 (3): 225–31. DOI: 10.2500/ajra.2014.28.4031.
8. Simonova O.I. Mukoliticheskaia terapiia v pediatrii: mify i real'nost'. Pediatrich. farmakologiia. 2009; 6 (2): 72–5. [in Russian]
9. Blotskii A.A., Tsepliaev M.Iu. Effektivnost' kompleksnoi terapii ostrykh i khronicheskikh sinusitov s primeneniem preparatov iz gruppy prirodnykh sekretolitikov. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2015; 21 (3): 47–53. [in Russian]
10. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol 2008; 4: 1119–29. DOI: 10.1517/17425255.4.8.1119.
11. Agnew JE, Bateman JRM, Pavia D, Clarke SW. Peripheral airways mucus clearance in stable asthma is improved by oral corticosteroid therapy. Bull Eur Physiopath Respir 1984; 20: 295–301.
12. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004; 125: 52–60. PMID: 14872001.
13. Dąbrowski P, Leszczyńska M, Mielcarek-Kuchta D. The role of carbocystein in the treatment of sinusitis. Otolaryngol Pol 2012; 66 (4): 15–9. DOI: 10.1016/S0030-6657(12)70779-5.
14. Carpagnano GE, Resta O, Foschino-Barbaro MP et al. Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate. Eur J Pharmacol 2004; 505: 169–75.
15. McPhail GL, Acton JD, Fenchel MC et al. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr 2008; 153: 752–7. DOI: 10.1016/j.jpeds.2008.07.011.
16. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 629–36.
17. Tirouvanziam R, Conrad CK, Bottiglieri T et al. High-dose oral Nacetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006; 103: 4628–33. DOI: 10.1073/pnas.0511304103.
18. Linden M, Wieslander E, Eklund A et al. Effects of oral Nacetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur Respir J 1988; 1: 645–50.
19. Eklund A, Eriksson O, Hakansson L et al. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J 1988; 1: 832–8.
20. Niederman MS, Rafferty TD, Sasaki CT et al. Comparison of bacterial adherence to ciliated and squamous epithelial cells obtained from the human respiratory tract. Am Rev Respir Dis 1983; 127: 85–90. DOI: 10.1164/arrd.1983.127.1.85.
21. Guibas GV, Spandou E, Meditskou S et al. N-acetylcysteine exerts therapeutic action in a rat model of allergic rhinitis. Int Forum Allergy Rhinol 2013; 3 (7): 543–9. DOI: 10.1002/alr.21145.
22. Boman G, Bäcker U, Larsson S et al. Oral acetyl cystine reduces exacerbation rate in chronic bronchitis, report of a trial organized by the Swedish Society for Pulmonary Disease. Eur J Respir Dis 1983; 64: 405–15.
23. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 29 (7): CD001287. DOI: 10.1002/14651858.CD001287.pub5.
24. Moretti M, Marchioni CF. An overview of erdosteine antioxidant activity in experimental research. Pharmacol Res 2007; 55: 249–54. DOI: 10.1016/j.phrs.2006.12.006.
25. Rhee CK, Kang CM, You MB et al. Effect of fudosteine on mucin production. Eur Respir J 2008; 32: 1195–202. DOI: 10.1183/09031936.00018508.
26. Otorinolaringologiia: natsional'noe rukovodstvo. Pod red. V.T.Pal'chuna. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2016. [in Russian]
27. McNeer RR, Huang D, Fregien NL, Carraway KL. Sialomucin complex in the rat respiratory tract: a model for its role in epithelial protection. Biochem J 1998; 330 (2): 737–44.
28. Perez-Giraldo C, Rodriguez-Benito A, Moran FJ et al. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. JAC 1997; 39: 643–6.
29. Drago L, De Vecchi E, Mattina R, Romanò CL. Activity of N-acetyl-L-cysteine against biofilm of Staphylococcus aureus and Pseudomonas aeruginosa on orthopedic prosthetic materials. Int J Artif Organs 2013; 36 (1): 39–46. DOI: 10.5301/ijao.5000135.
30. Leite B, Gomes F, Teixeira P et al. Combined effect of linezolid and N-acetylcysteine against Staphylococcus epidermidis biofilms. Enferm Infecc Microbiol Clin 2013; 31 (10): 655–9. DOI: 10.1016/j.eimc.2012.11.011.
31. Citation LG, Di MT, Sergio F et al. Effect of high N-acetylcysteine concentrations on antibiotic activity against a large collection of respiratory pathogens. Antimicrob Agents Chemother 2016; 60: 7513–7. DOI: 10.1128/AAC.01334-16.
32. Schwandt LQ, Van Weissenbruch R, Stokroos I et al. Prevention of biofilm formation by dairy products and N-acetylcysteine on voice prostheses in an artificial throat. Acta Otolaryngol 2004; 124 (6): 726–31.
33. Dinicola S, De Grazia S, Carlomagno G, Pintucci JP. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol 2014; 18 (19): 2942–8.
34. Macchi A, Ardito F, Marchese A et al. Efficacy of N-acetyl-cysteine in combination with thiamphenicol in sequential (intramuscular/aerosol) therapy of upper respiratory tract infections even when sustained by bacterial biofilms. J Chemother 2006; 18 (5): 507–13. DOI: 10.1179/joc.2006.18.5.507.
35. Sadovskii V.I., Sukharev A.A., Chernysh A.V. Sovremennoe lechenie gnoinoi infektsii v otorinolaringologii. Otorinolaringologiia Vostochnaia Evropa. 2016; 1 (22): 140–3. [in Russian]
Авторы
С.А.Карпищенко1, С.И.Алексеенко2,3, О.М.Колесникова*1
1 ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова» Минздрава России. 197022, Россия, Санкт-Петербург, ул. Льва Толстого, д. 6/8;
2 ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.Мечникова» Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41;
3 ГБУЗ «Детская городская больница №19 им. К.А.Раухфуса». 191036, Россия, Санкт-Петербург, Лиговский пр., д. 8
*olga_lozo@mail.ru
1 ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова» Минздрава России. 197022, Россия, Санкт-Петербург, ул. Льва Толстого, д. 6/8;
2 ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.Мечникова» Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41;
3 ГБУЗ «Детская городская больница №19 им. К.А.Раухфуса». 191036, Россия, Санкт-Петербург, Лиговский пр., д. 8
*olga_lozo@mail.ru
________________________________________________
S.A.Karpishchenko1, S.I.Alekseenko2,3, O.M.Kolesnikova*1
1 I.M.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation. 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8;
2 I.I.Mechnikov State Northwestern Medical University of the Ministry of Health of the Russian Federation. 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41;
3 K.A.Raukhfus Children City Hospital. 191036, Russian Federation, Saint Petersburg, Ligovskii pr., d. 8
*olga_lozo@mail.ru
1 I.M.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation. 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8;
2 I.I.Mechnikov State Northwestern Medical University of the Ministry of Health of the Russian Federation. 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41;
3 K.A.Raukhfus Children City Hospital. 191036, Russian Federation, Saint Petersburg, Ligovskii pr., d. 8
*olga_lozo@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.